APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

• Published in: Lancet neurology Vol. 20; no. 1; pp. 68 - 80
• Main Authors: Serrano-Pozo, Alberto, Das, Sudeshna, Hyman, Bradley T
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-01-2021; Elsevier Limited
• Subjects: Alleles; Alzheimer Disease - drug therapy; Alzheimer Disease - genetics; Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Alzheimer's disease; Animal models; Animals; Apolipoprotein E; Apolipoproteins E - drug effects; Apolipoproteins E - genetics; Apolipoproteins E - metabolism; Biomarkers; Blood-brain barrier; Brain; Clinical trials; Cognitive ability; Dementia; Genes; Genetic Therapy; Genome-wide association studies; Genomes; Genotype & phenotype; Haplotypes; Health risk assessment; Heparan sulfate; Humans; Isoforms; Microglia; Mutation; Neurodegeneration; Neurodegenerative diseases; Neuropathology; Pathology; Pathophysiology; Peptides; Risk factors; Tau protein; β-Amyloid
• ISSN: 1474-4422; 1474-4465
• DOI: 10.1016/S1474-4422(20)30412-9

The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE with amyloid-β peptide aggregation and clearance, over the past 5 years our understanding of APOE pathogenesis has expanded beyond amyloid-β peptide-centric mechanisms to tau neurofibrillary degeneration, microglia and astrocyte responses, and blood–brain barrier disruption. Because all these pathological processes can potentially contribute to cognitive impairment, it is important to use this new knowledge to develop therapies directed at APOE. Several therapeutic approaches have been successful in mouse models expressing human APOE alleles, including increasing or reducing APOE levels, enhancing its lipidation, blocking the interactions between APOE and amyloid-β peptide, and genetically switching APOE4 to APOE3 or APOE2 isoforms, but translation to human clinical trials has proven challenging.